KIDNEY RESEARCH UK

• ◆

  4 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

1. KIDNEY RESEARCH UK 2005-09-21 → present
2. THE NATIONAL KIDNEY RESEARCH FUND 1998-08-07 → 2005-09-21
3. NATIONAL KIDNEY RESEARCH FUND LIMITED(THE) 1967-05-12 → 1998-08-07

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Moore Kingston Smith LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Group structure

1. KIDNEY RESEARCH UK · parent
   1. Kidney Research Enterprises Limited 1% · England and Wales · undertake trading and retail activities for the benefit of Kidney Research UK.

Significant events

• “In May 2025, when the World Health Organisation adopted a resolution to reduce the burden of kidney disease, we celebrated this significant milestone for the whole kidney community.”
• “With 2025 marking the midway point of our ten-year charity strategy, together with our patient advisors, we have reflected on progress to date and have strengthened plans to increase the pace and impact of our work.”
• “In July 2025 the plan was announced and without any specific recommendations on the kidney disease pathway, it became clear we would have to advocate for kidney disease to be included among the promised condition-specific modern service frameworks to roll out effective care and prevention strategies.”
• “Our annual research investment last year exceeded £1lm for the first time, taking the number of active funded research studies to 128 and maximising opportunities to increase the pace and impact of positive change on kidney health through collaboration, funding and innovation.”
• “This year we were proud to launch The LifeArc-Kidney Research UK Centre for Rare Kidney Diseases, which will lead to improved diagnostics, treatments, and potentially cures, for thousands of adults and young people living with rare kidney diseases, addressing an enormous unmet need.”
• “In July 2024, we launched our report, Time To Act: A New Review of Kidney Health Inequalities, using it to call for urgent action to address the issues which put some people at greater risk of kidney disease and impede access to treatment and care.”
• “Launched in March 2025 by Boehringer Ingelheim and in partnership with the NHS, two projects under the SPOT CKD (Screening, Prevention, Outreach and Treatment for Health Equity) initiative are running in Hampshire and the Isle of Wight, and North East and North Cumbria.”
• “In Scotland, we launched a new action plan for chronic kidney disease. This lays out the steps and investment needed by the government to improve the monitoring of people with diabetes and heart disease who are at most risk of CKD.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

9

last 12 months

Capital events

0

last 24 months

Officers appointed

3

last 12 months

Officers resigned

4

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -25%

  £6,377,000 → £4,785,000

• Net assets

  -13.6%

  £14,404,000 → £12,440,000

• Employees

  +10.6%

  85 → 94

• Wages

  +12.9%

  £2,819,000 → £3,182,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers